Taking people in United StatesNo phase

Tests blood pressure lowering medicine to extend pregnancy in preeclampsia

Tests blood pressure medicine in pregnant women with preeclampsia or high blood pressure.

Key facts

Who runs it: University of Alabama at Birmingham
Where: Birmingham and New Orleans, United StatesSee the 2 sites
Trial code: NCT05676476
Registry title: The ACHIEVE Trial: Achieving Longer Gestation in Preeclampsia Via Antihypertensive Therapy.
Status: Recruiting
People taking part: 132 people, planned
Started: 14 Feb 2023
Expected to end: Jun 2027
Type of study: Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested: Antihypertensive treatment
Record updated: 12 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with high blood pressure caused by pregnancy, without the severe form of preeclampsia. It tests whether lowering blood pressure to below 140/90 mmHg lengthens the pregnancy.

Age: 14 Years to 49 Years
Sex: Women only
Disease stage: Gestational hypertension or preeclampsia without severe features, at 23 weeks 0 days to 35 weeks 6 days of pregnancy, with no reason for delivery at enrollment and a plan to continue the pregnancy.

Main reasons for not taking part

Preeclampsia with severe features, such as blood pressure of 160/110 mm Hg or more, low platelets, impaired liver or kidney function, fluid in the lungs, or lasting headache or vision problems
Stage 2 chronic hypertension
Known kidney problems before 20 weeks of pregnancy
Poor growth of the baby, too little amniotic fluid, or a known major structural or chromosomal abnormality of the baby
Cannot take labetalol and nifedipine XL, or ruptured membranes (waters broken)

This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant women

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

Pregnant women
Gestational age: 23 weeks, 0 days to 35 weeks, 6 days
Hypertensive disorder of pregnancy including gestational hypertension or preeclampsia, the non-severe form at enrollment, which is called without severe features by the American College of Obstetricians and Gynecologists
No evidence of the severe form of preeclampsia, termed severe features, as outlined in maternal exclusions
No indication for delivery at the time of enrollment
Planned expectant management at time of enrollment
Singleton or dichorionic twin gestation, defined at and beyond 14 weeks gestation. (A pregnancy complicated by a vanishing twin in the first trimester defined as less than 14 weeks gestation will be eligible.)
Intact membranes

Who cannot take part

Systolic blood pressure of 160 mm Hg or more, or diastolic blood pressure of 110 mm Hg or more on two occasions at least 4 hours apart (unless antihypertensive therapy is initiated before this time)
Impaired liver function that is not accounted for by alternative diagnoses and as indicated by abnormally elevated blood concentrations of liver enzymes (to more than twice the upper limit normal concentrations), or by severe persistent right upper quadrant or epigastric pain unresponsive to medications
New-onset headache unresponsive to medication and not accounted for by alternative diagnoses
Fetal growth restriction (lower than 10th percentile) at enrollment, based on an ultrasound within 3 weeks prior to enrollment
Oligohydramnios defined by amniotic fluid deepest vertical pocket <2 cm based on an ultrasound within the 48 hours prior to enrollment
Stage 2 chronic hypertension
Thrombocytopenia defined as: lower than 100 x 10e9 platelets/L
Renal insufficiency (serum creatinine concentration more than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease)
Underlying renal dysfunction defined as, presenting the following parameters prior to 20 weeks gestation: baseline creatinine, equal to or higher than, 1.2 mg/dL Or proteinuria: defined as presenting protein in urine, equal to or higher than, 300 mg/24 hours or protein/creatinine ratio, equal to or higher than, 0.3 or Urine dipstick reading of greater than or equal to 2 at baseline and in the absence of a urinary tract infection
Preeclampsia with severe features, defined per ACOG as:
Pulmonary edema
Visual disturbances
Contraindications to labetalol and nifedipine XL according to the FDA package insert
Patient unable to or unwilling to adhere to management recommendations
Fetal Reasons for Study Ineligibility:
Known major structural or chromosomal abnormality

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 14 and 49 years old?

Where in United States

University of Alabama at BirminghamBirmingham, United StatesContact: Rachel SinkeyTaking people
OschnerNew Orleans, United StatesContact: Sherri Longo, MDTaking people

About the trial

What the trial wants to find out

The Achieve Trial is a randomized clinical trial to test whether lowering blood pressure to less than 140/90 mmHg in women with hypertensive disorders of pregnancy will prolong pregnancy.

The 2 groups in the trial

InterventionTreatment being tested
Antihypertensive treatment for a BP goal of less than 140/90 mmHg
Treatment: Antihypertensive treatment
Usual CareNo study treatment, for comparison
Antihypertensive treatment only if BP ≥ 160/110 mmHg